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Background
The current standard of treatment for locally advanced
cervical cancer consists of external radiation plus brachy-
therapy concurrent with weekly applications of cisplatin.
On the other hand, current evidence suggests that preop-
erative chemoradiation is at least as effective as the stand-
ard treatment. Because limitations in the availability of
brachytherapy in Mexico and many other developing
countries, it is of major interest to determine whether a
radical hysterectomy after external chemoradiation has
superior or at least equivalent results in terms of survival
to chemoradiation and brachytherapy. In FIGO stages
IB2-IIA patients.
Patients and methods
This is a non-randomized comparison of both treatment
modalities. The data of preoperative chemoradiation
modality was taken from the cisplatin arm of a rand-
omized phase II study we performed comparing preoper-
ative chemoradiation with cisplatin against cisplatin/
gemcitabine (IJROBP 2005). These forty patients were
paired against a cohort of 40 patients treated with external
radiation and cisplatin plus brachytherapy. In both
groups, the dose of external radiation was 50 Gy in 2 Gy
fractions and cisplatin was dosed at 40 mg/m2 for six
weekly applications. Survival was analyzed with the Kap-
lan-Meier method and curves compared with the Log-rank
test.
Results
There were no significant differences in the clinicopatho-
logical characteristics of the patients. Mean age was 45
years (range 24 – 70). In both groups the histologies were
squamous cell carcinoma (70%), adenocarcinoma
(20%), and adenosquamous (10%). Stage distribution
according to the FIGO was as follows: IB2, 22.5%; IIA,
10%; IIB, 67.5%, in both groups. Overall, 100% of
patients completed external beam, and surgery or intrac-
avitary brachyterapy. The majority of patients received the
planned six courses of weekly cisplatin. At median follow-
up (28 months; range 2–58 months), overall survival is
78% and 75% (p > 0.05) for the surgical and brachyther-
apy groups of patients.
Conclusion
The results of this non-randomized comparison suggest
that these treatment modalities are equivalent in terms of
survival. A randomized study is ongoing to confirm these
results.
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